The Fall M&A Pipeline Is Stacked. Your Practice Might Be on a Buyer's List.

A practice collecting $1.5 million with $170,000 in normalized earnings is worth $1.02 million at the bottom of this fall's multiple range and $2.04 million at the top. The dentistry is identical. The difference is almost entirely accounting, staffing depth, and how much of the earnings survive a buyer's accountant, and nearly all of it is decided 12 to 24 months before anyone sends a letter of intent.

Here is the claim an informed owner can argue with: the surge of buyer interest this fall tells you nothing about what your practice is worth, and owners who read inbound calls as a valuation signal are the ones who sign the worst deals. A buyer contacting you is not a compliment. It's a data entry.

69% of DSOs Say They're Buying More. That's a Statement About Them.

The pipeline is real. TUSK Practice Sales reported in its Q2 2026 Dental Market Report that 69% of DSOs expect to increase acquisition activity in 2026, 78% anticipate a recapitalization within 12 to 36 months, and transactions are pricing at EBITDA multiples of roughly 6x to 12x. That is a stacked buyer pipeline by any definition.

It sits on top of a decade of consolidation. ADA Health Policy Institute research published in Health Affairs found dentists affiliated with private equity nearly doubled, from 6.6% in 2015 to 12.8% in 2021. DSO affiliation overall moved from 8.8% in 2017 to 10.4% in 2019 to 13% in 2022, and reached 16.1% of U.S. dentists as of 2024. The direction has not wavered in nine years.

None of that is a price quote for your practice. Acquisition appetite sets how many calls you get. Your financial statements set what the caller will pay. Those two things are only loosely related, and most owners collapse them into one feeling: somebody wants me, so I must be worth the top of the range.

The 6x to 12x band is not a menu. The top of it belongs to multi-site groups with multiple associates, a non-owner-dependent hygiene engine, and $1 million or more in platform-quality earnings. A single-location practice where the owner personally produces two thirds of the production is not competing in that bracket, no matter how many emails land this quarter.

The $1,020,000 Spread on One Practice

Run the arithmetic on a specific practice so the gap stops being abstract.

Say they collect $1,500,000. Operating expenses before any owner compensation run $1,050,000, which is 70% of collections. Pre-owner cash flow is $450,000.

That $450,000 is not EBITDA, and this is where most owners' internal valuation falls apart. A buyer is purchasing a business, not a job, so the owner's clinical labor gets replaced at market rate. If the owner personally produces $1,000,000 of that collection and the local associate rate is 28%, the buyer books $280,000 of replacement compensation.

Adjusted EBITDA: $170,000.

At 6x, that practice prices at $1,020,000. At 12x, it prices at $2,040,000. The spread is $1,020,000 on identical chairs, identical patients, identical clinical quality.

Now the part worth internalizing. Every single point of overhead on $1,500,000 in collections is $15,000 of EBITDA, and at a realistic 8x it is $120,000 of purchase price. Three points of overhead, which is one bad supply contract and one overstaffed front desk, is $360,000 of enterprise value.

Suppose this owner spends the next 14 months doing two unglamorous things: moving $21,000 of personal spending off the practice P&L so it stops being a deduction nobody will add back without documentation, and adding a second hygiene day that nets $24,000 in contribution. EBITDA goes to $215,000. At the same 8x, the practice prices at $1,720,000 instead of $1,360,000. That's $360,000 of additional proceeds for $45,000 of annual improvement.

Our view: that $360,000 is the most profitable 14 months of work available to a practice owner in their fifties, and almost nobody does it, because it produces nothing visible until the day it produces everything.

What Most Owners Get Wrong About Inbound Buyer Calls

The specific mistake, and it's made most often by owners aged 52 to 62 with a single location and strong collections: treating the volume of inbound interest as evidence of their own number, and then negotiating the multiple instead of fixing the earnings.

Buyers running an acquisition pipeline are canvassing geography. They pull state license rosters, practice management directories, and hygiene-day counts, and they contact every solo owner in a target metro. A dozen outreach emails means you have an address in a desirable county. It does not mean a dozen parties have modeled your P&L, because none of them have seen it.

What happens next is predictable. The owner, now convinced the market is hot, engages one buyer, shares statements, and gets a letter of intent at a headline number that assumes the owner's own add-backs are legitimate. Then the quality-of-earnings review starts, and the number drops: the family car, the continuing education trip that was mostly a vacation, the spouse on payroll without a defined role, the owner comp normalization nobody modeled. The headline price was 8.5x of a number that doesn't exist. The closing price is 6x of a number that does.

By then the owner has spent four months in diligence, told their accountant they're selling, and emotionally left the practice. Walking away feels impossible. That is not an accident of the process. That is the process.

We wouldn't share a P&L with any buyer before an outside party has normalized the earnings and stress-tested the add-backs. Not a broker the buyer recommended. Your own.

78% Expect a Recapitalization, and You're Riding in the Back

The single most under-read number in that TUSK report is the 78% anticipating a recapitalization within 12 to 36 months. If you sell into a platform and take part of your price in that platform's equity, your proceeds are not finished when you close. They settle at the recap.

Take that same practice at 8x: $1,360,000 of total consideration. A 70/30 structure means $952,000 in cash at close and $408,000 in rollover equity. If the platform recaps at a strong multiple on grown earnings, that $408,000 can genuinely double. If the platform recaps into a softer credit market, or if the group's same-store numbers sag because integration broke the schedule in half its offices, a 25% markdown on that stake is $102,000 of your sale price that quietly evaporates.

Rollover equity is a bet on somebody else's operating skill, priced by somebody else's exit timing, with no mechanism for you to influence either. Sometimes it's the best part of the deal. It is never the safe part of the deal, and owners are routinely sold it as though it were.

Three Line Items Diligence Will Find

Every quality-of-earnings review goes to the same three places first, and every owner is surprised by at least one.

• Owner compensation. Whatever you pay yourself is irrelevant. The buyer substitutes a market associate rate for the production you personally generate, and if you produce 70% of the practice at a 35% effective rate, the hit is enormous. Shifting production to an associate before you sell converts a valuation penalty into a valuation input.
• Add-backs without paper. A deduction you can't document with an invoice and a business purpose is not an add-back. It's a reduction in your price multiplied by 6 to 12.
• Hygiene dependence on you. A hygiene department that requires the owner on site for exams is a scheduling constraint a buyer has to solve. One where hygiene runs at full capacity under any licensed dentist is earnings that transfer intact.

Why 27% of Newer Dentists Going DSO Is Your Succession Problem

Here is the second-order squeeze. ADA Health Policy Institute data show more than 1 in 4 dentists within 10 years of graduation, 27%, were DSO-affiliated in 2024. That is the exact population you would recruit as an associate, a partner, or an internal buyer.

Which means the consolidation trend doesn't just produce buyers for your practice. It also drains the pool of people who could have bought it from you directly, or who could have taken over enough production to make your earnings transferable in the first place. The owners who most need an associate to de-risk their valuation are competing for that associate against groups offering signing bonuses, student loan help, and no management duties.

Our call: if you plan to transition within five years and you have no associate, recruiting one is not a staffing project. It's the highest-return item on your valuation list, and it's getting harder every year you wait.

Four Things to Do Before Thanksgiving

Pull your last 12 months of financials and have someone outside your practice calculate adjusted EBITDA with a market associate rate substituted for your clinical production, so you know your real number before a buyer tells you theirs. Separate every personal expense from the practice P&L effective this quarter, because a clean 2027 is worth more than a defended 2026. Reply to buyer outreach with a single question about structure, cash at close, and rollover percentage, and send nothing until you've got all three in writing. And start the associate search now, not after you've decided to sell.

What we're watching into Q4: whether the stated acquisition appetite actually clears at the quoted multiples, or whether letters of intent get repriced during diligence at a higher rate than last year. If closed multiples on single-location practices hold above 6x through the winter while recap activity accelerates, we'll revise toward the view that sellers really do have pricing power right now. If the gap between letter-of-intent prices and closing prices keeps widening, the pipeline is a volume story, not a price story, and every owner reading their inbox as a valuation should slow down.

If you want to know what a buyer's accountant will actually do to your earnings before one of them does it, the place to start is your own normalized EBITDA, not a rule of thumb about collections. Our valuation calculator substitutes a market associate rate for owner production and strips unsupported add-backs the same way diligence will, so you can see which end of the 6x to 12x range you're honestly standing in. Run your own numbers before you answer the next email.